MAM-2201 (4′-methyl-AM-2201, 5″-fluoro-JWH-122) is a drug that presumably acts as a potent agonist for the cannabinoid receptors.It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in the Netherlands and Germany in June 2011 as an ingredient in synthetic cannabis smoking blends.Like RCS-4 and AB-001,MAM-2201 thus appears to be a novel compound invented by “research chemical” suppliers specifically for grey-market recreational use. Structurally, MAM-2201 is a hybrid of two known cannabinoid compounds JWH-122 and AM-2201.
Identified as present in certain synthetic cannabis blends, MAM-2201 is a potent agonist, which acts upon the cannabinoid receptors (CB1 and CB2).
With its effects thought to be similar to those of Tetrahydrocannabinol (THC), the Cannabis plant’s active ingredient, this substance is crying out for in-depth research. With nothing published regarding its pharmacology, it offers a great opportunity for those whose interests lie in the area of cannabinoids to discover more.
Its for the purposes of in vitro research only, MAM-2201 is sold on the understanding that it isn’t for human consumption.